PKvitality Announces First-In-Human Clinical Results at the 15th ATTD Conference


PKvitality officially attended Europe’s most anticipated conference on Advanced Technologies and Treatments for Diabetes (ATTD) – from April 27-30, 2022, in Barcelona.
On this occasion, the results of the First-In-Human Clinical Trials of K’Watch Glucose have been presented in an e-poster by Timothy Bailey, Principal Investigator of the trial and CEO of AMCR Institute. These clinical results will be explained, on-site, by Minh Lê, General Manager of PKvitality.

Check out our e-poster and presentation audio here.

The trials led by PKvitality were successful and showed great user experience and tracking. The trial took place at AMCR Institute, a clinical research center focused on diabetes and obesity with worldwide renowned medical device expertise in the metabolic area. Non-invasive, precise and affordable, K’Watch will change the everyday lives of diabetics!

You might also like: